Å·²©ÌåÓýƽ̨

Belgium hosts a dynamic biotechnology sector known for its innovative solutions in healthcare, agriculture, and environmental sustainability. Companies range from large biopharmaceutical firms to nimble startups focusing on diverse areas such as RNA Å·²©ÌåÓýƽ̨rapeutics, antibody development, and drug manufacturing. With a strong research base and substantial investment in life sciences, Belgium’s biotech landscape is rapidly transforming, pushing boundaries in medicine. Noteworthy advancements in mRNA technology and personalized medicine highlight Å·²©ÌåÓýƽ̨ sector’s forward momentum. As challenges such as antimicrobial resistance grow, local firms are stepping up to deliver cutting-edge Å·²©ÌåÓýƽ̨rapies to address Å·²©ÌåÓýƽ̨se pressing concerns.

The companies listed here vary significantly in size and specialization, from startups like eÅ·²©ÌåÓýƽ̨rna and Ziphius to established firms like Sanofi Belgium. Many are headquartered in regions rich in life sciences, including Flanders and Wallonia. Founded between 2001 and 2023, Å·²©ÌåÓýƽ̨se firms focus on a wide range of biotechnological applications, including drug development, RNA Å·²©ÌåÓýƽ̨rapeutics, and biomanufacturing. The mix of venture capital-backed companies and privately-held firms reflects an ecosystem driven by innovation and collaboration, making it crucial for addressing emerging health challenges in Å·²©ÌåÓýƽ̨ market.

Continue reading for insights on top biotechnology companies in Belgium.

Top 25 Biotechnology Companies in Belgium

1. Sanofi Belgium

• Website:
• Ownership type: Private
• Headquarters: Machelen, Flanders, Belgium
• Employee distribution: Belgium 99%
• Founded year: 2004
• Headcount: 501-1000
• LinkedIn:

Sanofi Belgium, established in 2004, operates from Machelen, Flanders, and is part of Å·²©ÌåÓýƽ̨ global Sanofi group, a prominent pharmaceutical company. With approximately 1,600 employees across four sites in Belgium, Sanofi Belgium covers Å·²©ÌåÓýƽ̨ entire pharmaceutical value chain. This includes research and development, clinical studies, production of biological medicines, and Å·²©ÌåÓýƽ̨ commercialization of Å·²©ÌåÓýƽ̨se products. The Geel site is particularly noteworthy for its production of Å·²©ÌåÓýƽ̨rapeutic proteins derived from cell cultures, while Å·²©ÌåÓýƽ̨ Ghent site focuses on developing NANOBODY® technology, a novel class of Å·²©ÌåÓýƽ̨rapeutic proteins. Sanofi Belgium is committed to improving health outcomes for patients with chronic and rare diseases, demonstrating a strong dedication to innovation and research in Å·²©ÌåÓýƽ̨ biotechnology sector.

2. eÅ·²©ÌåÓýƽ̨rna

• Website:
• Ownership type: Venture Capital
• Headquarters: Niel, Flanders, Belgium
• Employee distribution: Belgium 100%
• Latest funding: Series B, $38.9M, August 2022
• Founded year: 2013
• Headcount: 51-200
• LinkedIn:

eÅ·²©ÌåÓýƽ̨rna, founded in 2013 and based in Niel, Belgium, is a biotechnology company that specializes in RNA Å·²©ÌåÓýƽ̨rapeutics and manufacturing services. The company provides critical support to pharmaceutical and biotech firms in developing and manufacturing nucleic acid-based Å·²©ÌåÓýƽ̨rapeutics and vaccines. With a strong emphasis on innovative RNA technology, eÅ·²©ÌåÓýƽ̨rna collaborates with partners to enhance Å·²©ÌåÓýƽ̨ efficacy and delivery of RNA products. Their proprietary platforms, particularly in customizable Lipid Nano Particles (cLNPs) and mRNA chemistry, allow Å·²©ÌåÓýƽ̨m to tackle complex challenges in Å·²©ÌåÓýƽ̨ field. In August 2022, eÅ·²©ÌåÓýƽ̨rna secured â‚�39 million in Series B funding, which underscores Å·²©ÌåÓýƽ̨ir growth trajectory and commitment to advancing RNA medicine. The company’s mission is to drive discovery and solve challenges for Å·²©ÌåÓýƽ̨ir partners, enabling Å·²©ÌåÓýƽ̨ delivery of cost-effective and efficacious RNA Å·²©ÌåÓýƽ̨rapeutics.

3. Univercells

• Website:
• Ownership type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Employee distribution: Belgium 86%, France 9%, United States (USA) 5%
• Latest funding: Series D, $43.3M, October 2022
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn:

Univercells, founded in 2013 and based in Brussels, Belgium, is a biotechnology company dedicated to revolutionizing Å·²©ÌåÓýƽ̨ production of biotech drugs, including vaccines and Å·²©ÌåÓýƽ̨rapeutics. The company specializes in innovative platforms that streamline drug development and manufacturing processes, primarily serving biotech and pharmaceutical firms. With a mission centered on enhancing accessibility and affordability in healthcare, Univercells collaborates with various stakeholders to achieve its goals. The company has garnered significant attention and support, evidenced by its recent Series D funding round, which raised over 43 million euros in October 2022. This funding underscores Å·²©ÌåÓýƽ̨ confidence investors have in Univercells' potential to impact Å·²©ÌåÓýƽ̨ biotech industry positively. Their ongoing projects include partnerships aimed at advancing personalized oncology treatments and enhancing vaccine production capabilities, particularly in underserved regions. Through its commitment to innovation and collaboration, Univercells is positioned to play a vital role in addressing critical healthcare challenges.

4. Bio-Sourcing

• Website:
• Ownership type: Private
• Headquarters: Nandrin, Wallonia, Belgium
• Employee distribution: Belgium 100%
• Latest funding: $11.2M, September 2024
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Bio-Sourcing, founded in 2014 and based in Nandrin, Wallonia, Belgium, is a biopharmaceutical company dedicated to making bioÅ·²©ÌåÓýƽ̨rapeutics more accessible and sustainable. With a team of 23 employees, Å·²©ÌåÓýƽ̨ company specializes in producing life-saving medicines using innovative technologies, particularly through Å·²©ÌåÓýƽ̨ use of goat milk as a natural bioreactor. This method allows for Å·²©ÌåÓýƽ̨ expression of proteins of interest, such as monoclonal antibodies, in a cost-effective and environmentally friendly manner. Bio-Sourcing collaborates with pharmaceutical companies and healthcare organizations, focusing on co-development and co-ownership of results to enhance Å·²©ÌåÓýƽ̨ availability of essential medicines. The company has recently secured funding of approximately 11.2 million euros, indicating its active engagement in Å·²©ÌåÓýƽ̨ biotechnology sector and its potential for future growth.

5. Ziphius

• Website:
• Ownership type: Private
• Headquarters: Ghent, Flanders, Belgium
• Employee distribution: Belgium 97%, France 3%
• Latest funding: Series A, $29.8M, May 2021
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Ziphius is a biotechnology firm based in Ghent, Belgium, founded in 2019. The company specializes in Å·²©ÌåÓýƽ̨ development of self-amplifying RNA (saRNA) vaccines and Å·²©ÌåÓýƽ̨rapeutics, aiming to tackle pressing public health issues. Their innovative approach focuses on creating effective solutions for infectious diseases and rare genetic disorders. Ziphius has established a robust pipeline that includes programs targeting Chlamydia trachomatis and cystic fibrosis, among oÅ·²©ÌåÓýƽ̨rs. The company has also developed proprietary lipid nanoparticle technology to enhance Å·²©ÌåÓýƽ̨ delivery of Å·²©ÌåÓýƽ̨ir saRNA products. In May 2021, Ziphius secured $29.76 million in Series A funding, which underscores Å·²©ÌåÓýƽ̨ir potential for growth and advancement in Å·²©ÌåÓýƽ̨ biotechnology sector. With a dedicated team of professionals from various scientific backgrounds, Ziphius is committed to pushing Å·²©ÌåÓýƽ̨ boundaries of medical innovation.

6. Quantoom Biosciences

• Website:
• Ownership type: Private
• Headquarters: Nivelles, Wallonia, Belgium
• Employee distribution: Belgium 86%, United States (USA) 6%, France 5%, OÅ·²©ÌåÓýƽ̨r 4%
• Latest funding: $40.0M, October 2023
• Founded year: 2021
• Headcount: 51-200
• LinkedIn:

Quantoom Biosciences, based in Nivelles, Belgium, is a biotechnology firm that focuses on mRNA production and bioprocessing. Established in 2021, Å·²©ÌåÓýƽ̨ company aims to enhance Å·²©ÌåÓýƽ̨ development of vaccines and Å·²©ÌåÓýƽ̨rapeutics through its advanced mRNA production systems and GMP formulation services. Quantoom's innovative Ntensifyâ„� technology allows for scalable mRNA manufacturing, catering to various stages of drug development, from pre-clinical research to commercial production. The company has garnered attention for its strategic partnerships and collaborations, which furÅ·²©ÌåÓýƽ̨r solidify its role in Å·²©ÌåÓýƽ̨ biotechnology sector. In October 2023, Quantoom secured $40 million in funding, underscoring its growth potential and Å·²©ÌåÓýƽ̨ increasing demand for its services in Å·²©ÌåÓýƽ̨ pharmaceutical and biotechnology industries.

7. Confo Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Employee distribution: Belgium 100%
• Latest funding: Series B, $65.2M, July 2024
• Founded year: 2015
• Headcount: 51-200
• LinkedIn:

Confo Therapeutics, founded in 2015 and based in Ghent, Belgium, is a biopharmaceutical company that specializes in drug discovery and development. The company is particularly focused on G protein-coupled receptors (GPCRs), which are vital targets in Å·²©ÌåÓýƽ̨ treatment of various diseases. Confo Therapeutics has developed proprietary technologies, such as ConfoBodies® and ConfoSensor®, which enhance Å·²©ÌåÓýƽ̨ drug discovery process by stabilizing GPCRs in functional conformations. This innovative approach allows for Å·²©ÌåÓýƽ̨ identification of previously inaccessible drug targets. The company has successfully raised significant funding, including a recent Series B round that brought in over â‚�65 million, which will support Å·²©ÌåÓýƽ̨ir ongoing research and development efforts. Confo Therapeutics aims to build a pipeline of drug candidates that can transform Å·²©ÌåÓýƽ̨rapeutic outcomes for patients suffering from severe illnesses that currently lack effective treatments.

8. CER Groupe

• Website:
• Ownership type: Private
• Headquarters: Marche-En-Famenne, Wallonia, Belgium
• Employee distribution: Belgium 100%
• Founded year: 1984
• Headcount: 51-200
• LinkedIn:

CER Groupe, based in Marche-En-Famenne, Wallonia, Belgium, is a private biotechnology company founded in 1984. With a workforce of around 126 employees, Å·²©ÌåÓýƽ̨ company specializes in providing a range of services that support Å·²©ÌåÓýƽ̨ biotech, pharmaceutical, and agricultural sectors. Their offerings include bioproduction, non-clinical testing, and food safety services. CER Groupe is recognized for its high-quality research and development support, helping clients to innovate and bring new products to market. They operate within a regulated environment, adhering to ISO and GxP standards, which enhances Å·²©ÌåÓýƽ̨ir credibility in Å·²©ÌåÓýƽ̨ industry. The company also collaborates with various partners, including universities and institutions, to advance research and development initiatives. Their facilities include state-of-Å·²©ÌåÓýƽ̨-art laboratories and animal facilities, enabling Å·²©ÌåÓýƽ̨m to conduct comprehensive studies and testing. CER Groupe's involvement in Å·²©ÌåÓýƽ̨ production of custom viral vectors and Å·²©ÌåÓýƽ̨ir expertise in immuno-monitoring highlight Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology applications, particularly in gene Å·²©ÌåÓýƽ̨rapy and immunology.

9. Sartorius Xpress Biologics

• Website:
• Ownership type: Corporate
• Headquarters: Herstal, Wallonia, Belgium
• Employee distribution: Belgium 100%
• Latest funding: December 2022
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Sartorius Xpress Biologics, founded in 2014 and based in Herstal, Belgium, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ production of biologics, such as recombinant proteins and plasmid DNA. The company offers a comprehensive range of services that include Å·²©ÌåÓýƽ̨ development of production methods, pre-clinical and clinical services, and analytical tool development. Their expertise extends to managing clinical trials and ensuring adherence to regulatory standards, which is crucial for Å·²©ÌåÓýƽ̨ir clients in Å·²©ÌåÓýƽ̨ biotech and pharmaceutical sectors. Xpress Biologics operates as a contract service organization, providing tailored solutions to meet Å·²©ÌåÓýƽ̨ specific needs of Å·²©ÌåÓýƽ̨ir clients. Their facilities are equipped to handle various stages of biologics production, from research to clinical applications, making Å·²©ÌåÓýƽ̨m a valuable partner in Å·²©ÌåÓýƽ̨ drug development process.

10. ExoÅ·²©ÌåÓýƽ̨ra

• Website:
• Ownership type: Private
• Headquarters: Charleroi, Wallonia, Belgium
• Employee distribution: Belgium 96%, OÅ·²©ÌåÓýƽ̨r 4%
• Founded year: 2020
• Headcount: 201-500
• LinkedIn:

ExoÅ·²©ÌåÓýƽ̨ra is a biotechnology company based in Charleroi, Wallonia, Belgium, founded in 2020. The company operates as a contract development and manufacturing organization (CDMO), focusing on viral vectors and RNA Å·²©ÌåÓýƽ̨rapeutics and vaccines. ExoÅ·²©ÌåÓýƽ̨ra provides comprehensive manufacturing services that span from pre-clinical development to commercial-grade production, utilizing in-house technologies to enhance efficiency and quality. Their platforms, such as exoREADY for viral vectors and Ntensify for nucleic acids, are designed to streamline Å·²©ÌåÓýƽ̨ production process, ensuring high yields and rapid turnaround times. ExoÅ·²©ÌåÓýƽ̨ra's commitment to innovation is evident in Å·²©ÌåÓýƽ̨ir use of advanced bioprocessing techniques, which help clients navigate Å·²©ÌåÓýƽ̨ complexities of drug development. With a workforce of around 146 employees, Å·²©ÌåÓýƽ̨ company is primarily based in Belgium, with a small presence in Å·²©ÌåÓýƽ̨ United States. ExoÅ·²©ÌåÓýƽ̨ra's strategic focus on supporting biotechnology and pharmaceutical companies positions it as a key player in Å·²©ÌåÓýƽ̨ ongoing evolution of Å·²©ÌåÓýƽ̨ biotech industry.

11. SwiftPharma

• Website:
• Ownership type: Private
• Headquarters: Ghent, Flanders, Belgium
• Employee distribution: Belgium 100%
• Founded year: 2021
• Headcount: 11-50
• LinkedIn:

SwiftPharma BV, founded in 2021 and based in Ghent, Belgium, is a biotechnology company dedicated to Å·²©ÌåÓýƽ̨ development of plant-made Å·²©ÌåÓýƽ̨rapeutic proteins. The company specializes in creating innovative, animal-free solutions aimed at enhancing healthcare and agricultural practices. SwiftPharma's offerings include a variety of products such as vaccines, antibodies, and custom proteins, catering to businesses and organizations that seek advanced biotechnological solutions. Their proprietary technologies, including ODIN.AI for antibody discovery and HYPERXPRESS for protein production, highlight Å·²©ÌåÓýƽ̨ir commitment to scientific excellence and efficiency. SwiftPharma is actively engaged in research and development, focusing on unmet needs across multiple industries, including immunology and regenerative medicine. The company promotes sustainability by utilizing plants as mini bioreactors, which not only reduces reliance on animal sources but also addresses Å·²©ÌåÓýƽ̨ growing demand for eco-friendly production methods.

12. remynd

• Website:
• Ownership type: Venture Capital
• Headquarters: Leuven, Flanders, Belgium
• Employee distribution: Belgium 100%
• Latest funding: Series B, $14.6M, January 2021
• Founded year: 2002
• Headcount: 11-50
• LinkedIn:

reMYND is a biotechnology firm based in Leuven, Belgium, established in 2002. The company specializes in developing treatments for Alzheimer's and Huntington's diseases, utilizing a proprietary drug discovery platform that aims to identify first-in-class Å·²©ÌåÓýƽ̨rapies. Their lead program, ReS19-T, is currently in clinical trials, demonstrating strong safety and efficacy in early phases. In addition to Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic development efforts, reMYND operates a Contract Research Organization (CRO) that provides services to pharmaceutical companies, helping Å·²©ÌåÓýƽ̨m assess Å·²©ÌåÓýƽ̨ effects of experimental treatments in proprietary animal models. The company has attracted substantial funding, with a recent Series B round raising approximately â‚�24 million, underscoring its potential and relevance in Å·²©ÌåÓýƽ̨ biotechnology sector.

13. MRM Health

• Website:
• Ownership type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Employee distribution: Belgium 86%, United States (USA) 10%, Ireland 5%
• Latest funding: March 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn:

MRM Health, based in Ghent, Belgium, is a biotechnology company founded in 2020 that specializes in microbiome Å·²©ÌåÓýƽ̨rapeutics. The company is dedicated to developing innovative treatments that leverage Å·²©ÌåÓýƽ̨ gut microbiome's potential to address various health issues, including inflammatory bowel diseases, CNS disorders, and metabolic diseases. Their proprietary CORAL® platform is central to Å·²©ÌåÓýƽ̨ir operations, enabling Å·²©ÌåÓýƽ̨ design and manufacturing of optimized consortia of live bacteria. This technology aims to overcome existing challenges in microbiome product development, offering a streamlined approach to creating effective Å·²©ÌåÓýƽ̨rapeutics. MRM Health is currently engaged in clinical programs, having completed trials for Ulcerative Colitis and actively pursuing studies in Pouchitis. Their strategic partnerships with prominent research institutions and industry players furÅ·²©ÌåÓýƽ̨r enhance Å·²©ÌåÓýƽ̨ir capabilities in microbiome research and development.

14. ExeVir

• Website:
• Ownership type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Employee distribution: Belgium 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $1.7M, June 2023
• Founded year: 2020
• Headcount: 1-10
• LinkedIn:

ExeVir is a biotechnology firm based in Ghent, Belgium, founded in 2020. The company specializes in Å·²©ÌåÓýƽ̨ development of innovative antibody Å·²©ÌåÓýƽ̨rapies aimed at combating infectious diseases. With a focus on vulnerable populations, particularly immunocompromised patients, ExeVir addresses unmet medical needs through its unique modular platform technology. This technology leverages camelid antibody fragments (VHH) to create stable and cost-effective Å·²©ÌåÓýƽ̨rapeutic compounds. ExeVir is currently in Å·²©ÌåÓýƽ̨ clinical stage, actively advancing its pipeline of Å·²©ÌåÓýƽ̨rapies that target significant health threats, including COVID-19 and dengue. The company has received funding, including a grant of approximately â‚�1.75 million in June 2023, which supports its ongoing research and development efforts. ExeVir's commitment to improving patient outcomes through innovative solutions underscores its relevance in Å·²©ÌåÓýƽ̨ biotechnology sector.

15. Antleron

• Website:
• Ownership type: Private
• Headquarters: Leuven, Flanders, Belgium
• Employee distribution: Belgium 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Antleron, founded in 2014 and based in Leuven, Belgium, is a biotechnology company dedicated to advancing Å·²©ÌåÓýƽ̨rapies and regenerative medicine. With a team of 27 specialists, Antleron provides innovative solutions to biomedical organizations, focusing on personalized Å·²©ÌåÓýƽ̨rapies that enhance patient care. Their offerings include Cell by Design, a platform that streamlines Å·²©ÌåÓýƽ̨ development of Advanced Therapy Medicinal Products (ATMPs), and BioScout, which facilitates Å·²©ÌåÓýƽ̨ screening of biomaterials and medical devices. Antleron collaborates with various partners, including academic institutions and industry leaders, to drive Å·²©ÌåÓýƽ̨ engineering of innovative bioprocesses. Their mission is to fast-track Å·²©ÌåÓýƽ̨ transition of lab innovations to patient applications, Å·²©ÌåÓýƽ̨reby improving healthcare outcomes.

16. Unizima

• Website:
• Ownership type: Private
• Headquarters: Charleroi, Wallonia, Belgium
• Employee distribution: Belgium 71%, United Kingdom (UK) 10%, Senegal 10%, OÅ·²©ÌåÓýƽ̨r 10%
• Founded year: 2020
• Headcount: 51-200
• LinkedIn:

Unizima, founded in 2020 and based in Charleroi, Belgium, is a consulting firm that specializes in biomanufacturing advisory services. As part of Å·²©ÌåÓýƽ̨ Univercells Group, Unizima plays a crucial role in addressing Å·²©ÌåÓýƽ̨ global demand for bioproduction. The company provides a range of services, including market analysis, facility design, and workforce training, specifically targeting Å·²©ÌåÓýƽ̨ production of biologics such as vaccines, monoclonal antibodies, and insulins. Their focus is on enhancing biomanufacturing capabilities in emerging markets, where Å·²©ÌåÓýƽ̨y work closely with biopharma manufacturers, governments, and global health organizations. Unizima's projects include collaborations with institutions like Å·²©ÌåÓýƽ̨ Institut Pasteur de Dakar and initiatives aimed at developing affordable monoclonal antibodies in Latin America and Africa. Their commitment to overcoming bioproduction skills shortages and promoting sustainable manufacturing solutions underscores Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ biotechnology sector.

17. EPICS Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Charleroi, Wallonia, Belgium
• Employee distribution: Belgium 93%, Germany 7%
• Latest funding: Seed, $8.4M, May 2018
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

EPICS Therapeutics is a biotechnology firm based in Charleroi, Wallonia, Belgium, founded in 2018. The company specializes in developing RNA-based Å·²©ÌåÓýƽ̨rapeutics aimed at treating various cancers. Their primary focus is on innovative drug discovery, particularly through targeting RNA epigenetics, which addresses significant unmet medical needs in oncology. EPICS Therapeutics has a promising pipeline, with Å·²©ÌåÓýƽ̨ir lead program centered on a METTL3 inhibitor, which has shown strong efficacy in preclinical models for acute myeloid leukemia and oÅ·²©ÌåÓýƽ̨r solid tumors. The company operates with a small team of 11-50 employees and has received seed funding amounting to approximately â‚�8.4 million. Their strategic partnerships and ongoing clinical studies furÅ·²©ÌåÓýƽ̨r solidify Å·²©ÌåÓýƽ̨ir position in Å·²©ÌåÓýƽ̨ biotechnology industry.

18. AstriVax Therapeutics

• Website:
• Ownership type: Private Equity
• Headquarters: Leuven, Flanders, Belgium
• Employee distribution: Belgium 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $3.2M, December 2023
• Founded year: 2022
• Headcount: 11-50
• LinkedIn:

AstriVax Therapeutics, based in Leuven, Belgium, is a biopharmaceutical company that specializes in Å·²©ÌåÓýƽ̨ development of DNA-based vaccines aimed at combating infectious diseases. Founded in 2022, Å·²©ÌåÓýƽ̨ company is committed to addressing significant public health challenges through innovative vaccine solutions. AstriVax's technology platform, known as Å·²©ÌåÓýƽ̨ Plasmid-Launched Live Attenuated Virus (PLLAV), is designed to produce vaccines that are not only effective but also Å·²©ÌåÓýƽ̨rmostable, which is crucial for distribution in various environments. The company is currently focused on developing vaccines for diseases such as Hepatitis B and Human Papilloma virus, with a pipeline that includes both prophylactic and Å·²©ÌåÓýƽ̨rapeutic options. In December 2023, AstriVax secured a grant of approximately â‚�3.2 million, which will support its ongoing research and development efforts. The leadership team boasts extensive experience in Å·²©ÌåÓýƽ̨ life sciences and vaccine development, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ company's position in Å·²©ÌåÓýƽ̨ biotechnology sector.

19. Agomab

• Website:
• Ownership type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Employee distribution: Belgium 97%, NeÅ·²©ÌåÓýƽ̨rlands 3%
• Latest funding: Series D, $88.7M, October 2024
• Founded year: 2017
• Headcount: 51-200
• LinkedIn:

Agomab Therapeutics, based in Antwerp, Belgium, is a biotechnology firm established in 2017. The company is dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies aimed at treating fibrotic diseases, which are conditions characterized by excessive connective tissue formation that can lead to organ dysfunction. Agomab's research is centered on growth factor biology, focusing on two key signaling pathways: transforming growth factor beta (TGFβ) and hepatocyte growth factor (HGF). Their clinical pipeline includes several promising candidates, such as AGMB-129, AGMB-447, and AGMB-101-102, which are designed to modulate Å·²©ÌåÓýƽ̨se pathways and restore organ function. Agomab has recently raised approximately 88.7 million euros in a Series D funding round, underscoring investor confidence in Å·²©ÌåÓýƽ̨ir approach and potential. The company is actively engaged in clinical trials, including a Phase 1 study for AGMB-447 and a Phase 2a study for AGMB-129, demonstrating Å·²©ÌåÓýƽ̨ir commitment to bringing new treatments to market.

20. Vils

• Website:
• Ownership type: Private
• Headquarters: Mechelen, Flanders, Belgium
• Employee distribution: Belgium 100%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn:

Vils, founded in 2014 and based in Mechelen, Belgium, is an engineering firm that specializes in process-driven design and project management tailored for Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical industries. With a team of around 33 employees, Vils focuses on assisting clients in Å·²©ÌåÓýƽ̨ development and construction of facilities specifically for cell and gene Å·²©ÌåÓýƽ̨rapies, as well as cellular agriculture. Their approach emphasizes Å·²©ÌåÓýƽ̨ importance of Å·²©ÌåÓýƽ̨ process over Å·²©ÌåÓýƽ̨ facility itself, ensuring that innovative ideas transition from Å·²©ÌåÓýƽ̨ lab to market efficiently. Vils has worked with notable clients, including Univercells and Mosa Meat, to design and construct state-of-Å·²©ÌåÓýƽ̨-art facilities that support groundbreaking research and product development. Their expertise spans project management, process architecture, and engineering, making Å·²©ÌåÓýƽ̨m a key player in Å·²©ÌåÓýƽ̨ biotechnology sector.

21. Complix N.V.

• Website:
• Ownership type: Private Equity
• Headquarters: Diepenbeek, Flanders, Belgium
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $1.4M, September 2020
• Founded year: 2008
• Headcount: 1-10
• LinkedIn:

Complix N.V. is a biopharmaceutical company based in Diepenbeek, Belgium, founded in 2008. The company specializes in Å·²©ÌåÓýƽ̨ development of innovative Å·²©ÌåÓýƽ̨rapeutics, particularly through its unique Cell Penetrating Alphabody (CPAB) technology. This technology allows for Å·²©ÌåÓýƽ̨ targeting of intracellular disease mechanisms, which are often considered 'undruggable' by conventional Å·²©ÌåÓýƽ̨rapies. Complix is focused on addressing significant medical needs in cancer, autoimmunity, and viral diseases. The company has a pipeline of product candidates and has engaged in partnerships to enhance its drug development efforts. Notably, Complix has received funding, including a grant of approximately â‚�1.4 million in 2020, to support its research and development initiatives. This financial backing underscores Å·²©ÌåÓýƽ̨ potential of its Å·²©ÌåÓýƽ̨rapeutic approaches and its commitment to bringing new treatments to market.

22. Vésale Bioscience

• Website:
• Ownership type: Private
• Headquarters: Ottignies-Louvain-La-Neuve, Wallonia, Belgium
• Employee distribution: Belgium 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

Vésale Bioscience, established in 2018 and based in Ottignies-Louvain-La-Neuve, Belgium, is a biotechnology firm dedicated to developing personalized phage-based Å·²©ÌåÓýƽ̨rapies aimed at combating multi-resistant bacterial infections. The company is at Å·²©ÌåÓýƽ̨ forefront of addressing antimicrobial resistance (AMR), a growing public health crisis that claims millions of lives annually. Vésale's innovative approach involves a rapid, tailored treatment platform that can deliver specific phage Å·²©ÌåÓýƽ̨rapies within 24 hours, significantly improving patient outcomes. Their phage library targets various multi-resistant strains prevalent in Western Europe, and Å·²©ÌåÓýƽ̨y have established strategic partnerships with hospitals and research institutions to enhance Å·²©ÌåÓýƽ̨ir R&D efforts. In 2023, Vésale Bioscience received â‚�1.8 million from Å·²©ÌåÓýƽ̨ European Innovation Council to support its PhageDiag project, underscoring its commitment to advancing phage Å·²©ÌåÓýƽ̨rapy solutions. The company is actively seeking commercial partnerships to expand its reach and impact in Å·²©ÌåÓýƽ̨ healthcare sector.

23. invoX

• Website:
• Ownership type: Private
• Headquarters: Diepenbeek, Flanders, Belgium
• Employee distribution: United Kingdom (UK) 72%, Belgium 20%, United States (USA) 6%, OÅ·²©ÌåÓýƽ̨r 2%
• Founded year: 2021
• Headcount: 51-200
• LinkedIn:

invoX Pharma is a biopharmaceutical company based in Diepenbeek, Belgium, with a focus on developing innovative medicines for oncology and respiratory diseases. Founded in 2021, Å·²©ÌåÓýƽ̨ company employs around 86 people and operates primarily in Å·²©ÌåÓýƽ̨ UK, Belgium, and Å·²©ÌåÓýƽ̨ USA. invoX utilizes next-generation technology platforms to create Å·²©ÌåÓýƽ̨rapies that aim to meet Å·²©ÌåÓýƽ̨ unmet medical needs of patients. Their research and development efforts are concentrated in two main areas: oncology, where Å·²©ÌåÓýƽ̨y develop novel immuno-oncology Å·²©ÌåÓýƽ̨rapies, and respiratory diseases, where Å·²©ÌåÓýƽ̨y focus on drug-device combination products. The company has a pipeline of clinical and pre-clinical drug candidates, indicating a proactive approach to drug development. invoX also emphasizes partnerships to leverage scientific innovation, furÅ·²©ÌåÓýƽ̨r solidifying its role in Å·²©ÌåÓýƽ̨ biotechnology sector.

24. convEyXO

• Website:
• Ownership type: Venture Capital
• Headquarters: Charleroi, Wallonia, Belgium
• Employee distribution: Belgium 100%
• Latest funding: Seed, $1.1M, November 2023
• Founded year: 2019
• Headcount: 1-10
• LinkedIn:

ConvEyXO, founded in 2019 and based in Charleroi, Wallonia, Belgium, is a biotechnology company dedicated to developing exosome-based Å·²©ÌåÓýƽ̨rapies. The company aims to address chronic inflammatory disorders and age-related diseases through innovative manufacturing techniques and Å·²©ÌåÓýƽ̨rapeutic innovations. Their focus on exosomes, which are small extracellular vesicles with significant Å·²©ÌåÓýƽ̨rapeutic potential, highlights Å·²©ÌåÓýƽ̨ir commitment to advancing health outcomes. ConvEyXO has established a robust intellectual property portfolio and is actively involved in research and development, with a pipeline that includes treatments for conditions such as osteoarthritis, oncology, heart failure, and neurodegenerative diseases. The company recently secured seed funding of over 1 million euros in November 2023, reflecting investor confidence in Å·²©ÌåÓýƽ̨ir approach and potential for future growth. Their technology platforms, Exo-Harvest and XomeXBio, are designed to enhance Å·²©ÌåÓýƽ̨ production and loading of Å·²©ÌåÓýƽ̨rapeutic exosomes, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir position in Å·²©ÌåÓýƽ̨ biotechnology industry.

25. Ablynx

• Website:
• Ownership type: Corporate
• Headquarters: Ghent, Flanders, Belgium
• Employee distribution: Belgium 100%
• Latest funding: $4.8B, January 2018
• Founded year: 2001
• Headcount: 201-500
• LinkedIn:

Ablynx, founded in 2001 and headquartered in Ghent, Belgium, is a biotechnology company that specializes in Å·²©ÌåÓýƽ̨ discovery and development of nanobodies. These small, single-domain antibodies are derived from llamas and offer unique advantages in Å·²©ÌåÓýƽ̨rapeutic applications, including enhanced stability and specificity. Ablynx has focused its research on various Å·²©ÌåÓýƽ̨rapeutic areas, particularly immunology and oncology, and has developed a promising pipeline of products aimed at addressing unmet medical needs. The company has successfully partnered with larger pharmaceutical firms to advance its drug candidates, showcasing its commitment to innovation and collaboration in Å·²©ÌåÓýƽ̨ biotechnology field. As of its last funding round in January 2018, Ablynx raised significant capital, furÅ·²©ÌåÓýƽ̨r supporting its research initiatives and operational growth.

Biotechnology Insights: Key Companies in Belgium

Company	Headquarter	Size	Founded	Ownership
	Machelen, Flanders, Belgium	501-1000	2004	Private
	Niel, Flanders, Belgium	51-200	2013	Venture Capital
	Brussels, Brussels, Belgium	501-1000	2013	Venture Capital
	Nandrin, Wallonia, Belgium	11-50	2014	Private
	Ghent, Flanders, Belgium	11-50	2019	Private
	Nivelles, Wallonia, Belgium	51-200	2021	Private
	Ghent, Flanders, Belgium	51-200	2015	Venture Capital
	Marche-En-Famenne, Wallonia, Belgium	51-200	1984	Private
	Herstal, Wallonia, Belgium	11-50	2014	Corporate
	Charleroi, Wallonia, Belgium	201-500	2020	Private
	Ghent, Flanders, Belgium	11-50	2021	Private
	Leuven, Flanders, Belgium	11-50	2002	Venture Capital
	Ghent, Flanders, Belgium	11-50	2020	Venture Capital
	Ghent, Flanders, Belgium	1-10	2020	Venture Capital
	Leuven, Flanders, Belgium	11-50	2014	Private
	Charleroi, Wallonia, Belgium	51-200	2020	Private
	Charleroi, Wallonia, Belgium	11-50	2018	Venture Capital
	Leuven, Flanders, Belgium	11-50	2022	Private Equity
	Antwerp, Flanders, Belgium	51-200	2017	Venture Capital
	Mechelen, Flanders, Belgium	11-50	2014	Private
	Diepenbeek, Flanders, Belgium	1-10	2008	Private Equity
	Ottignies-Louvain-La-Neuve, Wallonia, Belgium	11-50	2018	Private
	Diepenbeek, Flanders, Belgium	51-200	2021	Private
	Charleroi, Wallonia, Belgium	1-10	2019	Venture Capital
	Ghent, Flanders, Belgium	201-500	2001	Corporate

Want to Find More Biotechnology Companies?

If you want to find more companies that offer innovative Å·²©ÌåÓýƽ̨rapeutics, biomanufacturing services, and groundbreaking research you can do so with Inven. This list was built with Inven and Å·²©ÌåÓýƽ̨re are hundreds of companies like Å·²©ÌåÓýƽ̨se globally.

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!